Ambrose Healthcare Ltd (Ambrose Healthcare), an award-winning pharmaceutical company focused on rare diseases, has appointed an accomplished Medical Advisory Board to support the development of its growing pipeline.
Chaired by Professor Brian Feagan, the Medical Advisory Board is comprised of leading physicians with experience of rare diseases, international clinical studies and regulatory agencies.
Ambrose co-founder, Georgia Wilson Waterworth comments, “Appointing our Medical Advisory Board marks a strategic milestone for Ambrose – ahead of schedule we have secured the rights to two assets, and now look forward to formalising our work with these insightful experts as we prepare clinical trials for these products”.
“Each board member brings a unique and valuable contribution to our efforts to get effective treatments for rare diseases onto the market and into the hands of patients quickly.”
The four initial members of the Medical Advisory Board are Professor Brian Feagan, Dr Jamie Duckers, Dr Shabbir Moochhala and Professor Kevin Mills.
Prof. Brian Feagan MD, FRCPC
Professor of Medicine at the Schulich School of Medicine & Dentistry, Ontario - Canada
Dr Brian Feagan, a Gastroenterologist and Professor of Medicine, has dedicated his research to developing outcome measures for novel therapeutics and conducting large-scale multi-center clinical trials. With over 30 years of experience, he has authored over 550 articles, served as a Principal Investigator on more than 140 clinical trials and been named one of the top five experts globally for Crohn’s disease.
“In their previous company I worked with the founding team developing clinical trial plans, supporting interactions with regulatory agencies and executing international clinical trials as they developed their drug pipeline. Their standards of professionalism and delivery were exemplary, and I am looking forward to supporting them with their exciting new venture.”
Dr Jamie Duckers
National Clinical Lead for Rare Disease, NHS Wales - UK
Dr Jamie Duckers, a Respiratory Physician, has made significant contributions to healthcare and research in Wales. He serves as the National Clinical Lead for Rare Disease, Wales, and research lead for the All-Wales Adult Cystic Fibrosis Service, and is actively involved in various advisory groups related to cystic fibrosis and respiratory health. His experience also encompasses exploring early stakeholder engagement to ensure rare diseases patient priorities are being met early in the development of new drugs.
“New treatments for rare diseases are urgently needed – and I am excited to see that Ambrose is taking a different approach to the provision of new rare disease treatments. It’s exactly what is needed to support patients.”
Dr Shabbir Moochhala
Consultant nephrologist and physician, Royal Free Hospital - UK
Dr Shabbir Moochhala is an experienced consultant nephrologist at the Royal Free Hospital in London. He has specialist expertise in rare diseases and is a principal investigator for several international medical trials. He lectures internationally and leads in rare kidney disease at national level, including as chair of an NHS Rare Disease Collaborative Network in rare kidney stone disease.
“My patients encounter multiple hurdles: first finding a doctor who understands the nuances of their rare disease, and then overcoming the blocks and delays in drug development. Ambrose have a novel approach which could make a massive difference in my patients' lives, and at a much earlier stage. I am delighted to be supporting their efforts to change how we treat rare diseases."
Professor Kevin Mills
Head of the Translational and Clinical Omics Group at University College London based at the Great Ormond Street Institute of Child Health - UK
Professor Mills’ research aims to combine state-of-the-art technology with AI/Machine Learning to find new drug targets, identify new biomarkers and develop new and more precise tests. His research group is unique in that they can use their omic capability to help understand disease mechanisms and identify drug targets but can also translate any biomarker into a test to NHS or Industry accredited standards.
“Using new approaches is key to developing more effective orphan drugs. I am enthusiastic about Ambrose’s commitment to new technologies and large data sets as they explore new models for successful treatments in rare diseases.”
For more information, please contact:
Juliet Burns, Corporate Communications